#FDA approval

Talazoparib slowed disease progression compared to chemotherapy in EMBRACA study.

FDA also approves genetic test to identify eligible patients.

Human papillomavirus vaccine can prevent cervical, anal and oral cancers.

Vaccine has the potential to prevent 90 percent of HPV-related cancers.

Cemiplimab is the first treatment for metastatic or locally advanced cutaneous squamous cell carcinoma.

Targeted therapy approved first-line treatment of cancer with specific genetic mutations.

The combination led to better outcomes for people newly diagnosed with advanced non-small-cell lung cancer.

Immunotherapy approved for previously untreated patients with nonsquamous non-small-cell lung cancer.

Requires use of diagnostic tests for PD-L1 levels in tumor tissue from bladder cancer patients.

Responses were durable for at least six months in 77% of responders.

Study showed significant improvement in progression-free survival with lenvatinib compared to sorafenib.

Lenvima works as well as standard therapy for metastatic or unresectable cancer.

Poteligeo approved for mycosis fungoides and Sézary syndrome.

Azedra (iobenguane I 131) approved for pheochromocytoma or paraganglioma, tumors that can increase hormone production.

Sentimag platform helps determine if breast cancer has spread to sentinel lymph nodes.

First approval using a new FDA process to speed up cancer drug reviews.